Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of “Buy” from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned a consensus recommendation of “Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $18.08.

Several research analysts recently weighed in on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research report on Tuesday, February 11th.

Roivant Sciences Price Performance

Shares of ROIV opened at $10.71 on Wednesday. The stock has a 50-day moving average of $10.78 and a 200-day moving average of $11.48. The company has a market cap of $7.64 billion, a PE ratio of -71.40 and a beta of 1.26. Roivant Sciences has a one year low of $9.76 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Analysts expect that Roivant Sciences will post -0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the business’s stock in a transaction on Monday, January 13th. The shares were acquired at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the completion of the transaction, the director now directly owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. The trade was a 21.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the completion of the transaction, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,551,654.85. The trade was a 10.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,975,586 shares of company stock worth $22,640,661. Company insiders own 7.90% of the company’s stock.

Institutional Trading of Roivant Sciences

Hedge funds have recently modified their holdings of the company. US Bancorp DE raised its position in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the last quarter. Natixis Advisors LLC grew its stake in Roivant Sciences by 8.3% in the 3rd quarter. Natixis Advisors LLC now owns 153,717 shares of the company’s stock valued at $1,774,000 after acquiring an additional 11,726 shares during the period. Mutual of America Capital Management LLC grew its stake in Roivant Sciences by 12.5% in the 3rd quarter. Mutual of America Capital Management LLC now owns 367,866 shares of the company’s stock valued at $4,245,000 after acquiring an additional 40,787 shares during the period. Swiss National Bank grew its stake in Roivant Sciences by 1.0% in the 3rd quarter. Swiss National Bank now owns 721,046 shares of the company’s stock valued at $8,321,000 after acquiring an additional 6,900 shares during the period. Finally, Whalen Wealth Management Inc. purchased a new position in Roivant Sciences in the 3rd quarter valued at $224,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.